An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Trial Profile

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational
  • Sponsors Eisai Co Ltd; Eisai Inc
  • Most Recent Events

    • 28 Apr 2017 Results of exploratory analysis assessing the potential of perampanel as monotherapy using data from two prospective open-label extension studies (NCT00735397 and NCT01161524) and a retrospective study (NCT02736162), presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of a pooled analysis assessing the long-term efficacy and safety of adjunctive perampanel in patients from four phase II/III open-label extension studies (207, 307, 335 and 332), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 13 Apr 2017 According to an Eisai Inc media release, results assessing perampanel as monotherapy from studies (307, 235 and 504) will be presented at the American Academy of Neurology (AAN) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top